GW Pharma (GWPH) Posts Q3 Loss as Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
GW Pharma (GWPH) PT Lowered to $160 at Leerink Partners
August 8, 2017 10:23 AM EDTLeerink Partners lowered its price target on GW Pharma (NASDAQ: GWPH) to $160.00 (from $162.00) while maintaining a Outperform rating. GWPH announced 3Q EPS of (£0.13) which were in line with estimates of (£0.14).
GWPH has begun the rolling submission process for its Epidiolex filing and... More
